(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

COMBINAÇÃO DE INIBIDOR DE HDAC E ANTICORPO DE ANTI-PD-L1 PARA O TRATAMENTO DE CÂNCER OVARIANO

ArquivadaInvention PatentPCT · US2016068836

Application data

Number

112018013094

Type

Invention Patent

Filing

12/28/2016

Publication

12/11/2018

PCT

US2016068836

Progress at the INPI

  1. Filing12/28/16
  2. Publication12/11/18
  3. Abandoned
  4. Allowance
  5. Grant
  6. In force

The application was abandoned: examination was not requested within the 36 months following the 12/28/2016 filing, the deadline set by art. 33 of the Brazilian IP Act. The technology is in the public domain in Brazil.

Talk to a specialist

Latest action published by the INPI: 08/24/2021. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

MERCK PATENT GMBH

DE

PFIZER INC.

US

SYNDAX PHARMACEUTICALS, INC.

UM

See this company's full portfolio

Inventors

M. M. (pessoa física)

US

P. O. (pessoa física)

US

Technical data

Priority claims

US

62/271,914 · 12/28/2015

Abstract

São aqui descritos métodos para o tratamento de câncer ovariano recorrente, pesadamente pré-tratado. Em particular, são providos métodos para o tratamento de câncer ovariano recorrente, pesadamente pré-tratado, com uma combinação de entinostat e um anticorpo de an-ti-PD-L1.

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Adição na publicação

#15.35

08/24/2021

RPI 2642

Arquivamento definitivo - Art. 33 da LPI

#11.1.1

06/30/2020

RPI 2582

Arquivamento - Art. 33 da LPI

#11.1

02/04/2020

RPI 2561

Notificação de entrada na fase nacional - PCT

#1.3

12/11/2018

RPI 2501

Alteração de dados cadastrais

#1.1

07/03/2018

RPI 2478

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.